DRUG
Intranasal Oxytocin (IN-OXT)
24 UI oxytocin intranasal
Status
Recruiting
Phase
Phase 2
Enrollment
80
Locations
1
Results
Not posted
Publications
0
Study summary
Background: Borderline personality disorder (BPD) is a frequentand serious psychiatric disorder characterized by a persistent pattern of instability in relationships, affect and self-image. Although long-term follow-up prospective studies have shown high clinical remission rates, they also point out that usually persist social functioning deficits, comorbidity, isolation, chronic affective clinic and life dissatisfaction. Self-compassion training (SCT) could be an effective strategy targeting self-criticism, shame and chronic feelings of worthlessness, as well as increasing resilience. In addition, the administration of intranasal oxytocin has proven useful in regulating social cognition, affiliation behaviors and enhancing empathy, key symptoms in this population. This combined intervention could be particularly appropriate for BPD patients. Objective: The objective of this project is to implement and evaluate the effectiveness of a combined intervention, based on SCT and intranasal oxytocin administration, for the treatment of patients with BPD. Methodology: Controlled and randomized clinical trial. A self-compassion training of 5 weeks duration plus intranasal oxytocin administration versus SCT plus placebo will be compared in a sample of 80 patients with BPD. Clinical and wellness measures will be evalutated as outcomes.
Controlled clinical trial. A self-compassion training of 5 weeks duration plus intranasal oxytocin administration versus SCT plus placebo will be compared in a sample of 80 patients with BPD. Self-criticism, self-compassion, clinical and wellness measures will be evalutated as outcomes.
Interventions
DRUG
24 UI oxytocin intranasal
DRUG
24 UI intranasal placebo
BEHAVIORAL
SCT consists of a 5 sessions of Self-Compassions meditation training
Timeline
First posted
Apr 27, 2026
Study start
Jan 10, 2024
Primary completion
Jun 1, 2026
Study completion
Aug 1, 2026
Results posted
Not reported
Registry updated
Apr 27, 2026
Outcomes
Self Compassion Scale Short Form (SCS-SF)
Time frame · 1 month
Self-Compassion Scale (12 items, minimum 12-maximum 60). Higher scores worse
Forms of Self-Criticism/Self-Attacking and Self-Reassuring Scale-Short Form (FSCRS-SF)
Time frame · 1 month
Self-reported Self-Criticism scale (14 items, minimum 0- maximum 56). Higher scores worse
Borderline Symptoms List-23 (BSL-23)
Time frame · 1 week
Self-reported Borderline Symptoms scale (minimum 0- maximum 92). Higher scores worse
Satisfaction with life scale (SWLS)
Time frame · 1 month
Self-reported satisfaction with life scale (SWLS), well being (5 items, minimum 5 - maximum 25). Higher scores better
Pemberton Happiness Index (PHI)
Time frame · 1 month
Pemberton Happiness Index (minimum 0 - maximum 110). Higher scores better
OMS WHO-QOL-BREF( WHOQOL-Group, 1998).
Time frame · 2 weeks
Quality of life OMS (26 items, minimum 26 - maximum 130). Higher scores better
Eligibility
Inclusion Criteria: * Diagnosis of Borderline Personality Disorder (BPD) according to two semi-structured interviews: the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) and the Revised Diagnostic Interview for Borderlines (DIB-R). * Aged between 18 and 50 years, inclusive. * Pharmacological treatment stability maintained throughout the intervention period. * Previous treatment for BPD, specifically Standard Dialectical Behavior Therapy (DBT) or DBT Skills Training. * High levels of self-criticism, defined as scores \> 12 on the Inadequate Self (IS) subscale of the Forms of Self-Criticizing/Attacking \& Self-Reassuring Scale - Short Form (FSCRS-SF). Exclusion Criteria: * Presence of comorbid psychiatric disorders, including: Schizophrenia, Psychotic Disorders, Bipolar Disorder, Current Major Depressive Disorder (MDD), Substance Dependence, Organic Brain Disease, or Intellectual Disability, as determined by medical examination and clinical assessment using the SCID-I (Structured Clinical Interview for DSM-IV Axis I Disorders). * History of severe endocrine disorders. * History of medical conditions, specifically: Epilepsy, Renal Insufficiency (Kidney Failure), or Heart Failure. * Concurrent participation in any other psychotherapy or psychological treatment during the study period. * Women of childbearing potential who are unwilling or unable to use highly effective contraception (e.g., oral contraceptives, intrauterine device \[IUD\], partner's vasectomy, tubal ligation, or sexual abstinence) throughout the entire duration of the study. * Intention to become pregnant or planning a pregnancy during the course of the study. * Current pregnancy or breastfeeding at the time of enrollment or during the study. * Concomitant medical treatment that is incompatible with the administration of intranasal oxytocin.
Study locations
Spain. Showing up to 24 locations stored in the fast local snapshot.
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Wake Forest University Health Sciences · Total Hip Arthroplasty
Phase 2
Enrolling by invitation
80
2026-07
Yale University · Pain · Pituitary Surgery
Phase 2
Not yet recruiting
75
2026-07
Medical University of South Carolina · PTSD · Alcohol Use Disorder
Phase 2
Completed
175
2026-07
University Hospital, Tours · Cervical Ripening · Unfavorable Cervix
Phase 3
Recruiting
1,494
2026-07
Icahn School of Medicine at Mount Sinai · Pregnancy · Labor
Phase 3
Recruiting
281
2026-07
Elizabeth Austen Lawson · Vasopressin Deficiency
Phase 1
Recruiting
40
2026-07
Massachusetts General Hospital · Arginine Vasopressin Deficiency · Oxytocin Deficiency
Early Phase 1
Recruiting
20
2026-07
Aalto University · Induction of Birth · Cervical Ripening
Not applicable
Recruiting
40
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.